Hearing loss affects over 1.5 billion people worldwide and can have serious consequences for mental health and cognitive decline. While current treatments—such as hearing aids and cochlear implants—offer partial relief, they do not fully restore hearing function. Regenerative medicine, particularly stem cell therapy, is now being studied as a potential alternative.
Stem cell therapy in hearing loss research aims to address sensorineural hearing loss—the most common form—by replacing damaged auditory neurons in the inner ear. Rinri Therapeutics, a spinout from the University of Sheffield, is leading preclinical efforts with Rincell-1, a cell-based therapy derived from embryonic stem cells. The goal is to regenerate auditory neurons in the cochlea, reconnecting them to hair cells and the brainstem to restore hearing circuitry.
This approach differs from gene therapy, which targets specific genetic mutations, and instead aims to serve a broader population, including those with age-related or noise-induced hearing loss. Initial trials will explore combining Rincell-1 with cochlear implants to assess both objective and functional improvements.
Looking ahead, Rinri Therapeutics also plans to develop Rincell-2 and Rincell-3 using induced pluripotent stem cells (iPSCs), with scalability and long-term affordability in mind. If successful, stem cell therapy could mark a shift in how hearing loss is treated, moving beyond symptom management toward biological repair.
